From WikiProjectMed
Jump to navigation Jump to search
Trade namesCincain, Nupercainal, Nupercaine, Sovcaine, others
Other namesDibucaine, percaine[1]
  • 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
Clinical data
Drug classLocal anesthetic (amide)[2]
Main usesHemorrhoids, pruritus ani, minor burns, insect bites[3][4]
Side effectsRash, skin irritation[4]
Routes of
Topical, intravenous (for animal euthanasia)
External links
Legal status
Chemical and physical data
Molar mass343.471 g·mol−1
3D model (JSmol)
  • O=C(c1c2ccccc2nc(OCCCC)c1)NCCN(CC)CC
  • InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24) checkY

Cinchocaine, also known as dibucaine, is a local anesthetic used together with a corticosteroid to help with the symptoms of hemorrhoids and pruritus ani.[3] It may also be used for minor burns and insect bites.[4] It is applied to the area affected.[3]

Common side effects include rash and skin irritation.[4] Other side effects may include anaphylaxis.[4] It is an amide.[2] It is one of the stronger but also more toxic local anesthetics.[2]

Cinchocaine was first made in 1929.[1] It is available over the counter and as a generic medication.[4][5] In the United States a 30 gram tube costs about 5 USD as of 2021.[5] In the United Kingdom a version which includes a steroid costs about £6.[3]

Medical use

Cinchocaine is the active ingredient in some topical hemorrhoid creams such as Proctosedyl.[6] It is also a component of the veterinary drug Somulose, used for euthanasia of horses and cattle.

Physical properties

Cinchocaine is relatively insoluble in alkaline aqueous solutions.

See also


  1. 1.0 1.1 Woolfson, David; McCafferty, Dermot (1 March 1993). Percutaneous Local Anaesthesia. CRC Press. p. 56. ISBN 978-0-13-656372-3. Archived from the original on 11 January 2022. Retrieved 24 December 2021.
  2. 2.0 2.1 2.2 "MeSH Browser". Archived from the original on 14 May 2021. Retrieved 24 December 2021.
  3. 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 101. ISBN 978-0857114105.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "Dibucaine Monograph for Professionals". Archived from the original on 4 November 2021. Retrieved 24 December 2021.
  5. 5.0 5.1 "Compare Dibucaine Prices - GoodRx". GoodRx. Archived from the original on 12 November 2016. Retrieved 24 December 2021.
  6. "Proctosedyl ointment/suppositories (cinchocaine, hydrocortisone)". Netdoctor. June 2012. Archived from the original on 25 December 2019. Retrieved 25 December 2019.

External links

  • Abdel-Ghani N, Youssef A, Awady M (2005). "Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry". Farmaco. 60 (5): 419–24. doi:10.1016/j.farmac.2005.03.001. PMID 15910814.
  • Souto-Padron T, Lima AP, de Oliveira Ribeiro R (2006). "Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi". Parasitol Res. 99 (4): 317–20. doi:10.1007/s00436-006-0192-1. PMID 16612626. S2CID 5933459.
  • Nounou M, El-Khordagui L, Khalafallah N (2005). "Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles". Acta Pol Pharm. 62 (5): 369–79. PMID 16459486.
  • Aroti, A.; Leontidis, E. (2001). "Simultaneous Determination of the Ionization Constant and the Solubility of Sparingly Soluble Drug Substances. A Physical Chemistry Experiment ". Journal of Chemical Education. 78 (6): 786–788. doi:10.1021/ed078p786.